NCT03108469View on ClinicalTrials.gov

Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

April 26, 2019

Study Completion Date

April 26, 2019

Conditions
Chronic Migraine
Interventions
DRUG

IONIS-PKKRx (ISIS 546254)

Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.

OTHER

Placebo

Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.

Trial Locations (2)

63303

StudyMetrix, City of Saint Peters

65807

Clinvest Research, LLC, Springfield

Sponsors
All Listed Sponsors
collaborator

Clinvest Research, LLC

INDUSTRY

collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

Smith, Timothy R., M.D.

INDIV